MELBOURNE, Australia and SAN FRANCISCO, May 07, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to ...

Inc., a clinical-stage biotechnology company specializing in T cell receptor-engineered T cell therapies for cancer treatment, announced that an abstract has been accepted for poster presentation ...

May 06, 2025--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging ... today announced that three posters were presented at IMMUNOLOGY2025, the annual ...

BETHESDA, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and ...

Adagene Inc. announced a poster presentation for the ASCO 2025 conference ... which can enhance visibility and credibility within the biotechnology community. The updated results of the Phase ...

Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases,will be sharing oral and poster presentations at the ...

Latus Bio Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced upcoming oral and poster presentations at the American Society for Gene and Cell Therapy (ASGCT) ...

Presentation Summary: EQ504 is a strong inducer of the AhR pathway in intestinal epithelial cells, preserves the barrier function and promotes healing of intestinal epithelial cells by promoting ...